# CURB: adding SBRT for oligoprogressive breast or non-small-cell lung cancer

Source: https://onco.cc/key-papers/paper-curb-oligoprogression-lancet-2024/  
OnCo record `paper-curb-oligoprogression-lancet-2024` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CURB found longer progression-free survival overall with added SBRT, with different findings in its lung and breast cohorts. The small breast comparison did not show a statistically significant improvement.

## Summary

Open-label randomised phase 2 comparison after at least first-line systemic therapy in metastatic breast cancer or non-small-cell lung cancer with no more than five progressing lesions. The 2024 report randomised 106 patients: 51 to standard care and 55 to SBRT plus standard care. The primary endpoint was progression-free survival; the registry defines its clock from randomisation. Disease-site subgroup analysis was prespecified.

The overall median was 7.2 months with added SBRT versus 3.2 with standard care, hazard ratio 0.53. The NSCLC subgroup showed a longer median, while the breast subgroup’s estimate was imprecise and not statistically significant. Sixteen of 47 breast participants had TNBC; the combined breast result does not determine the effect in every subtype.

## Fields

- Kind: Key paper
- Last checked: 2026-11-09
- Tags: education-audit; local-treatment
- Journal: Lancet (London, England)
- Year: 2024
- DOI: 10.1016/s0140-6736(23)01857-3
- Authors: Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN, CURB Study Group.
- Findings: Overall progression-free survival: 7.2 versus 3.2 months with SBRT versus standard care; hazard ratio 0.53, 95 percent confidence interval 0.35 to 0.81.; NSCLC subgroup: 10.0 versus 2.2 months; hazard ratio 0.41, 95 percent confidence interval 0.22 to 0.75. Breast subgroup: 4.4 versus 4.2 months; hazard ratio 0.78, interval 0.43 to 1.43.; Grade 2 or worse adverse events occurred in 34 of 55 versus 21 of 51. Nine patients had SBRT-related grade 2 or worse toxicity, including pneumonitis and brachial plexopathy.
- What it means: Supports a setting-specific comparison of adding SBRT. Neither treated-site control nor this progression endpoint alone establishes an immune mechanism or a universal survival benefit.
- Caveats: The trial closed before its planned sample size after the preplanned interim efficacy analysis.; An imprecise nonsignificant breast comparison does not establish exactly zero effect in every breast-cancer population.; Oligoprogression after prior treatment differs from limited residual responding disease and newly limited metastatic disease.; The captured 2026 registry reports enrollment of 107, while this publication reports 106 randomised participants. The publication denominator is retained; no reason for the source difference is invented.

## Sources

- Primary publication identity and abstract: https://pubmed.ncbi.nlm.nih.gov/38104577/
- Full original report: https://pmc.ncbi.nlm.nih.gov/articles/PMC10880046/
- Registry: randomisation-based primary endpoint: https://clinicaltrials.gov/study/NCT03808662

## Connected records

- terms: [Systemic versus local therapy](https://onco.cc/terms/systemic-vs-local-therapy/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- trials: [CURB: SBRT for oligoprogressive breast or non-small-cell lung cancer](https://onco.cc/trials/curb-oligoprogression/)

---
JSON: https://onco.cc/api/v1/entities/paper-curb-oligoprogression-lancet-2024.json